Last reviewed · How we verify
Multiple dose insulin injections
At a glance
| Generic name | Multiple dose insulin injections |
|---|---|
| Also known as | MDI |
| Sponsor | Castilla-La Mancha Health Service |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Glycemic Variations During the Menstrual Cycle in Women With Type 1 Diabetes
- Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus (NA)
- Pediatric Insulin Plan Calculator for T1DM Management (NA)
- FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS) (PHASE2)
- A Phase 1 Study of [225Ac]-FPI-1434 Injection (PHASE1)
- Hybrid Closed Loop Effectiveness Trial in Adults With Type 1 Diabetes (NA)
- A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar (PHASE2, PHASE3)
- Adherence to Mediterranean Diet in Type 1 Diabetes Initiating Minimed 780G: Glucose Metrics vs Insulin Metrics, is There a Difference
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Multiple dose insulin injections CI brief — competitive landscape report
- Multiple dose insulin injections updates RSS · CI watch RSS
- Castilla-La Mancha Health Service portfolio CI